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BACKGROUND: Thiothymidine (S
4TdR) can be incorporated into DNA and sensitise cells to DNA damage and cell death following
exposure to UVA light. Studies were performed to determine if the combination of S
4TdR and UVA could be an effective treatment
for bladder cancer.
METHODS: Uptake and incorporation of S
4TdR was determined in rat and human bladder tumour cell lines. Measures of DNA
crosslinking and apoptosis were also performed. In vivo activity of the combination of S
4TdR and UVA was investigated in an
orthotopic model of bladder cancer in rats.
RESULTS: Thiothymidine (200mM) replaced up to 0.63% of thymidine in rat and tumour bladder cancer cells. The combination of
S
4TdR (10–200mM) and UVA (1–5kJm
 2) caused apoptosis and cell death at doses that were not toxic alone. Addition of
raltitrexed (Astra Zeneca, Alderley Edge, Cheshire, UK) increased the incorporation of S
4TdR into DNA (up to 20-fold at IC5) and
further sensitised cells to UVA. Cytotoxic effect was associated with crosslinking of DNA, at least partially to protein. Intravenous
administration of S
4TdR, in combination with UVA delivered directly to the bladder, resulted in an antitumour effect in three of five
animals treated.
CONCLUSION: These data indicate that the combination of S
4TdR and UVA has potential as a treatment for bladder cancer, and give
some insight into the mechanism of action. Further work is necessary to optimise the delivery of the two components.
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In the UK, transitional cell carcinoma (TCC) of the urinary bladder
is the fifth most commonly diagnosed malignancy with 10091 new
cases reported in 2007 (CRUK Cancer Statistics, 2010).
The prevalence of this disease significantly exceeds its primary
incidence as it has a high rate of recurrence ranging from 31% at
5 years for low-risk tumours to 78% at 5 years for high-risk
tumours (Babjuk et al, 2008). Bladder cancer can be broadly
classified based on two distinct molecular and histological TCC
pathologies – nonmuscle invasive bladder cancer (NMIBC) and
muscle invasive bladder cancer (MIBC) (Knowles, 2008). Approxi-
mately 75–85% of patients present with NMIBC (Parker et al,
1996), and these cancers are associated with a relatively benign
course rarely affecting survival, however, surveillance and
recurrence makes this an expensive disease to manage. In NMIBC,
the presence of multifocal disease, high-grade tumours or with
concomitant carcinoma in situ is associated with the molecular
biology of the aggressive variant of TCC (MIBC). These NMIBC
patients have a high risk of both recurrence and disease
progression into MIBC. Once there is MIBC, contemporary overall
survival at 5 years following cystectomy is 50–60% (Shariat et al,
2003). Intravesical Bacille Calmette-Gue ´rin (BCG) therapy is
currently the favoured treatment for high-risk patients despite
significant morbidity. Treatment with BCG reduces the odds of
progression by 27% in patients with intermediate- and high-risk
tumours (Sylvester et al, 2002). Patients who fail to respond to
BCG require radical and morbid surgery for the best possible
chance of a cure, and new approaches to reduce progression are a
clinical priority. As the bladder can be accessed readily via the
transurethral route, it is ideal for topical photosensitive treat-
ments, as exemplified by the increasing use of photodynamic
bladder cancer diagnostics, and this potential is further explored in
a preclinical model in this paper.
4-Thiothymidine (S
4TdR) is a pyrimidine nucleoside thio analogue.
Although it has close structural similarities to thymidine (TdR), the
two molecules have markedly different ultraviolet absorbance spectra.
Thymidine absorbs maximally at 270nm (UVC) while the peak
absorption of S
4TdR is in the UVA range at 340nm.
The altered photospectrum of S
4TdR enables it to form
photochemical DNA intrastrand crosslinks (Warren et al, 1998)
and DNA–protein crosslinks. These properties have been used
to investigate the structural and functional interactions of
DNA-binding proteins with synthetic oligonucleotides containing
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4TdR (Nikiforov and Connolly, 1992). Interstrand DNA crosslinks
are also formed and S
4TdR-containing oligonucleotides can be
photoligated in aqueous solution (Liu and Taylor, 1998).
Importantly, these types of photochemical DNA lesion in cellular
DNA are all potentially cytotoxic.
Thiothymidine incorporation into DNA and a consequent
sensitisation to UVA has been demonstrated in various cultured
skin cell lines (Massey et al, 2001; Reelfs et al, 2007). The cytotoxic
effect is hypothesised to result partly from the formation of bulky
DNA intrastrand crosslinks. Incorporation of S
4TdR is dependent
on the thymidine salvage pathway mediated by thymidine kinase
(TK). This raises the possibility that inhibiting de novo synthesis of
thymidine nucleotides might increase DNA S
4TdR incorporation
by forcing increased reliance on thymidine salvage. Raltitrexed (N-
(5[3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl]-N-methyla-
mino -2-thenoyl)-L-glutamic acid/‘Tomudex’/ZD1694) is a water
soluble quinazoline-based antifolate that is a specific inhibitor of
thymidylate synthase (TS), a key enzyme in the de novo pathway
(Jackson et al, 1983; Mitrovski et al, 1994). In bladder cancer cells,
TS inhibition results in both an increased TK activity and
upregulated expression of the nucleotide transporter protein to
maintain thymidylate levels through pyrimidine salvage (Pressacco
et al, 1995). It is hypothesised that raltitrexed might be used to
increase thiothymidine uptake into cells and incorporation into
DNA and subsequently to increase the sensitivity to UVA.
MATERIALS AND METHODS
Cell culture
MYU-3L (Kameyama et al, 1993; Kawamata et al, 1993), MBT2
(Soloway et al, 1973), RT4 (Rigby and Franks, 1970) and AY27
bladder cancer cell lines were cultured in RPMI-1640 medium
supplemented with 10% foetal bovine serum, penicillin and
streptomycin in a humidified atmosphere of 95% air, 5% CO2 at
371C. AY-27 TCC cells were a kind gift from Ronald Moore
(Professor of Surgery and Oncology, University of Alberta), and
were derived from primary rat tumours established by the oral
administration of FANFT.
Determination of the S
4TdR content of DNA
Thiothymidine was added to culture medium to achieve concen-
trations of 1–200mM for two cell-doubling times (Table 1).The
DNA was extracted using Qiagen DNeasy and converted to
deoxynucleosides by successive digestion with DNAse I (Sigma,
Poole, UK), nuclease P1 and alkaline phosphatase (Roche GmbH,
Mannheim, Germany). Quantification of S
4TdR and thymidine
nucleosides was carried out using a Perkin Elmer LC System
(Beaconsfield, Buckinghamshire, UK) coupled to an API-4000
LC/MS/MS Triple Quadrupole Mass Spectrometer (Applied
Biosystems, Warrington, UK), with Analyst software for data
acquisition and analysis. Separation was performed on a
Phenomenex 20 4.0mm Luna 3u C18 Mercury column. Mobile
phase consisted of 0.05 M NH3Ac pH 5.0/methanol at 0.2ml per
minute. Positive ESI mode was used with m/z 242.9/127.1 for
thymidine and m/z 259.1/143.0 for S
4TdR and the limits of
detection were 2.5 pg and 0.25 pg, respectively. The S
4TdR content
of DNA was expressed as the percentage of DNA thymidine
replaced by S
4TdR.
UVA exposure
Cells cultured in dishes or plates were exposed to UVA using a
Philips facial Studio HB 175 (Philips, Guildford, UK). The distance
between the plates and the lamp was measured to deliver a dose
rate of 5mWcm
 2 UVA. Under these conditions, a 1sec exposure
under the lamp corresponded to 0.05kJm
 2.
Determination of growth inhibition
Cells were cultured in the presence of S
4TdR for two cell-doubling
times. Plates were then exposed to UVA as described above and
were re-incubated for a further 72h. Cell growth was determined
using the Sulforhodamine B (SRB) assay (Skehan et al, 1990) and
growth inhibition expressed as a percentage of growth compared
with untreated controls.
Comet assay
The Comet assay was performed using components of the
CometAssayKit (Trevigen, Oxford, UK). For UVA exposure, cells
were detached from the dishes and re-suspended in PBS. Cells were
re-suspended at a concentration of 5 10
5 cellsml
 1 and mixed
with molten LM Agarose (Trevigen) in a ratio of 1:10 and 75mlo f
the suspension placed on Comet slides (Trevigen). Electrophoresis
was carried out for 20min at 1voltcm
 1 at 300mA. Slides were
stained with SYBR green and viewed under a Leica TCS SP2 UV
Confocal Laser Scanning Microscope. The SYBR green was excited
by the 488nm argon laser and the emission detected at
496–549nm. Analysis of comets was performed using Komet 5
software (Andor Technology, Belfast, Northern Ireland). Fifty
comets were analysed for each treatment group to give values for
the Olive tail moment and comet tail length.
Crosslinking was expressed as a percentage decrease in Olive tail
moment using the formula below as previously described (Hartley
et al, 1999).
%decreaseintailmoment ¼
1  
ðTMiS
4 TdR-UVA   TMContÞ
ðTMiCont   TMContÞ
 
 100
where TM iCont¼tail moment of irradiated control cells;
TM iS
4TDR-UVA¼tail moment of irradiated cells treated with
S
4TdR and UVA; TMCont¼tail moment of unirradiated control
cells.
To discriminate DNA–DNA crosslinks from DNA–protein
crosslinks, a proteinase K treatment was performed. After lysis,
slides were washed in TE buffer (10mM Tris, 1mM EDTA, pH 10),
then covered with 100ml proteinase K (Sigma) (1mgml
 1 TE
buffer) and incubated for 2h in a humidified incubator at 371C.
Controls were incubated with 100ml TE buffer only. Following
incubation, slides were processed as above.
Assessment of apoptosis
Caspase 3 and 7 activities were measured using the Caspase-Glo
Assay (Promega, Southampton, UK). The MYU-3L and AY27 cells
were incubated in the presence or absence of S
4TdR (100mM) for
two cell-doubling times and exposed to 10kJm
 2 UVA. Cells were
Table 1 S
4TdR incorporation into DNA following RTX treatment
%S
4TdR incorporation amount (fold increase)
a
Cell line
Doubling
time (h) No RTX IC5 RTX IC50 RTX
RT4 35 0.15 2.71 (19.7) 8.16 (59.1)
MYU-3l 26 0.22 1.55 (7.1) 2.48 (11.4)
MBT2 21 0.50 1.96 (3.9) 2.60 (5.2)
AY27 19 0.63 2.26 (3.6) 4.76 (7.6)
Data from cells cultured in 100mM S
4TdR with the stated concentrations of RTX for
two cell-doubling times. Fold increases in S
4TdR incorporation are relative to culture
with no RTX.
aThe amount of S
4TdR incorporated is expressed as the percentage of
TdR replaced by S
4TdR. (IC5 and IC50 concentrations: RT4 2.5nM, 5.6nM; MYU-3L
3.5nM, 17.5nM; MBT2 4.0nM, 8.1nM; AY27 0.5nM, 4.0nM, respectively).
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was added and luminescence was measured.
AY27 and MYU-3L cells treated with S
4TdR (100mM) and UVA
(10kJm
 2) were suspended and stained with Annexin V -FITC
(Beckman Coulter, High Wycombe, UK). Samples were analysed
by flow cytometry using BD FACScan II Flow cytometer (BD
Biosciences, Oxford, UK).
Orthotopic animal model
All in vivo work was carried out under strict regulatory approval
(LREC licence PPL 60/2836). Female Fischer rats (F344) weighing
170–200g were anaesthetised using inhaled isofluorane. Rats were
catheterised using a 20-gauge cannula. The bladder was precondi-
tioned using 0.1 N HCl to strip the epithelium and neutralised with
0.1N KOH followed by a PBS wash to create a surface suitable
implantation of tumour cells. Suspensions of MYU-3L cells
(1 10
5 in 0.4ml RPMI 1640 per 50% FCS) were instilled for 1h.
Rats were turned 901 every 15min to encourage even distribution
of tumour cells. Two days after tumour cell instillation, the
urothelium was completely denuded, with cancer cells overlying
oedematous subepithelial connective tissue. At day 5 post-
instillation, 80% of tumours showed invasion into the subepithelial
connective tissue consistent with stage pT1 tumours. The
subendothelial connective tissue showed increased vascularity
over normal rats’ bladders. Tumour depth varied between
0.2–1.4mm. By day 10, 100% of tumours progressed to muscle
invasive disease (pT2). At 21 days post-instillation, all tumours
were histological stage T3 with invasion into the perivesical fat and
areas of tumour necrosis. The progression to invasion in the
MYU-3L model without early metastases makes this a suitable
model of progression in high-risk NMIBC.
Administration of S
4TdR and UVA light
Thiothymidine solution was dissolved in sterile water up to doses
of 16mg in 0.4ml aliquots. An intravesical instillation time of 2h
was used. Intravenous injections of S
4TdR (160mgkg
 1) were
reconstituted in 1.0ml sterile water and administered via tail vein
injection. Whole bladder UVA exposure was achieved using a
UVCLEAN fibre optic system (Sensor Electronics, Coumbia, NC,
USA). This consisted of a portable power supply coupled to a UV
(320–340nm) light emitting diode set to the maximum power
setting (18mA). The UV clear optic fibre (0.6mm diameter) fitted
through the urethral cannula (20 gauge) without any leak. The
bladder was filled with 0.1ml sterile PBS to partially distend the
bladder and the fibre was advanced so that the tip sat 1–2mm
beyond the end of the cannula. Calculations using the surface area
of the fibre tip and the estimated surface area of the bladder (BSA)
using the equation BSA¼4.83(bladder volume)
2/3 in cm
2 (Xiao
et al, 2003) indicated that a 15min exposure would be equivalent
to 5kJm
 2 UVA delivery.
Measurement of thymidine and S
4TdR levels in rat serum
Thiothymidine concentrations in 100ml samples of rat plasma were
determined following acetonitrile protein extraction and comparison
with a standard curve of thymidine and S
4TdR in human plasma.
Dried samples were re-suspended in 200mlo fm o b i l ep h a s e( 0 . 0 5 M
NH3-Ac pH 5.0). Samples were analysed as described above.
Histopathology
To confirm that MYU-3L cells retained their carcinoma phenotype,
indirect immunoperoxidase staining of paraffin embedded bladder
tumour specimens with a pan–cytokeratin cocktail (Abcam, Cam-
bridge, UK) was performed using standard immunohistochemistry
protocols. Antigen retrieval was carried out using a citrate buffer and
bound antibody was detected using biotin-conjugated rabbit anti-
mouse immunoglobulins and the streptABC kit (DAKO, Ely,
Cambridgeshire, UK) and Sigmafast diaminobenzidine tablets (Sigma).
RESULTS
Thiothymidine is incorporated into the DNA of bladder
cancer cells in vitro
Each of the bladder carcinoma cell lines was assessed for the ability
to incorporate S
4TdR into DNA. Following culture in the presence
of 200mM S
4TdR for two cell-doubling times, the thiobase replaced
B 0.63% of DNA TdR in AY27 cells. Under the same conditions,
B 0.50% of DNA TdR was replaced by S
4TdR in MBT2 cells. The
extent of substitution in MYU-3L and RT4 cells was lower, at 0.22
and 0.15%, respectively (Figure 1). These levels of S
4TdR
incorporation are comparable to those reported in human
fibroblasts (Massey et al, 2001). When AY27 and MYU-3L cells
were cultured in a medium with 200mM thiothymidine, thiothy-
midine was detectable in DNA extracts after 2h of incubation,
replacing 0.23 and 0.05% for each cell line, respectively.
Raltitrexed increased S
4TdR incorporation into DNA. Under
similar conditions (200mM, two cell doublings), the addition of IC5
and IC50 concentrations of raltitrexed increased DNA S
4TdR
incorporation 7- and 11-fold, respectively, in MYU-3L cells. IC5
raltitrexed concentrations increased S
4TdR incorporation
4-, 20- and 4-fold, respectively, in MBT2, RT4 and AY27 cells
and these values were even higher at IC50 concentrations. These
findings are summarised in Table 1.
Thiothymidine sensitises bladder cancer cell lines to UVA
When MYU-3L cells were treated with a range of S
4TdR
concentrations and subsequently exposed to increasing UVA
doses, there was a S
4TdR- and UVA dose-dependent growth
inhibitory effect (Figure 2). In control experiments, no growth
inhibition was observed in cells treated with S
4TdR alone up to
300mM or with UVA at doses less than 50kJm
 2 (data not shown).
After 10 and 200mM S
4TdR and 1kJm
 2 UVA, growth inhibition
was 29 and 75%, respectively, increasing to 89 and 98% growth
inhibition at 5kJm
 2. Consistent with their more extensive DNA
substitution, a dose of 1kJm
 2 UVA produced 90 and 100%
growth inhibition in AY27 cells cultured in 10 and 200mM S
4TdR
(data not shown).
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Figure 1 Incorporation of S
4TdR into cellular DNA. Cell lines were
incubated in concentrations of S
4TdR as indicated on the x axis for two
cell-doubling times. Following DNA extraction and digestion, nucleosides
were analysed using LC/MS/MS to determine the percentage of DNA
thymidine replaced by S
4TdR (y axis).
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4TdR is further augmented by
raltitrexed
The enhanced DNA S
4TdR incorporation after raltitrexed treat-
ment was associated with increased UVA sensitivity. In the
absence of raltitrexed, 10mM S
4TdR and 0.5kJm
 2 UVA produced
a growth inhibition of 8% in MYU-3L cells (Figure 3). When
combined with a range of increasing raltitrexed concentrations
up to 7.5nM, the same S
4TdR concentration and UVA dose resulted
in a progressively increasing growth inhibition of up to 65%.
Raltitrexed also increased the S
4TdR/ UVA sensitivity of RT4,
MBT2 and AY27 cells. The results for MBT2 and AY27 were
comparable to those obtained for MYU-3L cells. Consistent
with the more pronounced effect of raltitrexed on DNA S
4TdR in
RT4, the differential sensitivity attributable to raltitrexed was
greatest in these cells. (Figure 3). In control experiments,
raltitrexed alone did not confer any additional sensitivity to
UVA (data not shown).
Thiothymidine causes DNA crosslinks and apoptosis
following UVA exposure
The DNA lesions induced by S
4TdR/UVA treatment were assessed
using the comet assay. The crosslinking of DNA S
4TdR was
measured as a reduction in comet tail moments in X-irradiated
cells. Typical comet images are shown in Figure 4. An X-ray dose
of 20Gy induced comets in the nondrug-treated control cells
(Figures 4A and G). The length of the comet tail was significantly
shorter in X-irradiated cells that had previously been treated with
200mM S
4TdR and 10kJm
 2 UVA. The mean reduction in Olive
tail moment by S
4TdR/UVA was 55 and 51% for MYU-3L and
AY27 cells, respectively, in three independent experiments. As
expected, there was no visible DNA migration in samples that were
not X-irradiated. To examine whether formation of DNA–Protein
crosslinks by S
4TdR /UVA contributed to the reduced DNA
migration, slides were treated with proteinase K before electro-
phoresis. Protease digestion caused a 24% increase in tail moment
compared with untreated slides (data not shown).
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Figure 3 Augmentation of UVA sensitisation using raltitrexed. Cells were cultured for two cell-doubling times with 20mM S
4TdR and RTX as indicated.
Cells were detached and re-plated in 96-well plates and irradiated under a thin layer of PBS (0.5kJm
 2 UVA for MYU-3L cells and 2.5kJm
 2 for RT4, MBT2
and AY27 cells). After irradiation, 150ml of fresh growth medium was replaced. Surviving cells were stained and scored after 5 days. All values represent the
mean±s.e.m. of 10 replicates.
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Figure 2 Sensitisation of MYU-3L bladder cancer cells to low doses of
UVA. MYU-3L cells were incubated in the presence of S
4TdR as indicated
in the legend for two cell-doubling times. Cells were exposed to UVA
(x axis) and re-incubated for a further 72h in fresh medium. Growth was
assessed using the SRB assay (y axis).
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bladder carcinoma cells
Twenty-four hours following treatment with 100mM S
4TdR and
10kJm
 2 UVA, cells appeared shrunken with condensed nuclei. By
18h after irradiation, caspase 3 and 7 activity in the culture
medium was increased by factors of 5.2 and 5.7 for MYU-3L cells
and AY27 cells, respectively, compared with controls (Figure 5).
The induction of apoptosis was confirmed by flow cytometry
analysis. By 18h after UV irradiation of cells pretreated with
100mM S4TdR, annexin binding was detectable in 29 and 26% of
MYU-3L and AY27 cells, respectively. The corresponding figures
for untreated cells were 5 and 7%.
Figure 4 Typical comet images from MYU-3L cells treated with S
4TdR and UVA. Thiothymidine treatment was for two cell-doubling times at 200mM and
UVA exposure was at 10kJm
 2. Irradiated cells were exposed to 20Gy X-irradiation. (A) Unirradiated control; (B) Unirradiated S
4TdR control;
(C) Unirradiated UVA control; (D) Unirradiated S
4TdR and UVA; (E) Irradiated S
4TdR control; (F) Irradiated UVA control; (G) Irradiated control;
(H) Irradiated S
4TdRþUVA.
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following intravenous or intravesical administration
Bladder tumours were successfully established in F334 Fischer rats
by instillation of MYU-3L bladder cancer cell suspensions into
preconditioned rats’ bladders. At day 2 after tumour implantation,
clumps of cells were visible in the bladder lumen with early
adherence to the denuded urothelium. By day 5 post-instillation,
stage pT1 bladder tumours were seen with infiltration into the
subepithelial connective tissue and tumour depth of o1mm.
Bladders were macroscopically identical to normal rat bladders.
Tumours stained positively with a pan–cytokeratin cocktail
confirming a carcinoma phenotype. Tumours showed a rapid
growth phase from day 6–21 with formation of bulky tumours
progressing to muscle invasive and locally advanced disease, but
without evidence of metastatic spread. Rat bladders examined
histologically between day 5 and day 21 showed tumour
development in 45 out of 50 animals inoculated with tumour cells.
Thiothymidine was detectable in bladder tumour DNA following
intravenous administration at a dose of 160mgkg
 1 (32mg for a
200g rat) one week after tumour seeding (Table 2). Tissues were
sampled 2h and 20h after injection and concurrent blood samples
were taken at the time of euthanasia. Specimens of bladder, kidney,
liver, skin and eye were obtained from three animals at each time
point – one control and two rats in which tumour cells were
implanted. Three tissue samples from each organ were analysed
per animal. At two hours post-injection, S
4TdR replaced
0.0018±0.0002% of thymidine in bladder tumour DNA, but was
undetectable in DNA from control bladders. By 20h, substitution
in tumour DNA had increased nearly 10-fold to 0.0140±0.0006%
and S
4TdR was present in DNA from control bladders at
0.0055±0.0002%. Thiothymidine was detectable in kidney and
liver DNA and the levels of substitution increased between 2 and
20h (Table 2). Incorporation into skin and eye was much lower
(o0.001%). Thiothymidine was cleared quite rapidly from blood;
serum concentrations were 27.7±2.0mM at 2h and 0.15±0.01mM
at 20h.
Intravesical instillation of S
4TdR was also examined. Thiothy-
midine (0.0040±0.0100%) was present in DNA of bladder tumours
immediately after installation for 2h (16mg in 0.4ml sterile water)
(Table 2). This was the maximum value observed and the level of
substitution decreased at 4 and 20h post-instillation to
0.0028±0.0010% and 0.0019±0.00003%. In control bladders,
S
4TdR was present at 0.0010% immediately following and at 4h
post-instillation, but was undetectable by 20h. A similar pattern
was observed for other organs, with a maximum S
4TdR
incorporation observed immediately after drug instillation and
decreasing with time (Table 2). Plasma S
4TdR concentration was
0.094mM immediately after intravesical instillation and 0.052mM 4h
later. Data were not available for the 20h time point.
Thiothymidine and UVA have antitumour activity in an
orthotopic model of bladder cancer
The effectiveness of S
4TdR/UVA as an anticancer treatment was
tested in the rat bladder tumour model. The experiment comprised
six treatment groups: no-treatment controls, intravenous S
4TdR
only, intravesical S
4TdR only, UVA only, intravenous S
4TdR plus
MYU-3L
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Figure 5 Caspase 3/7 activity following treatment with S
4TdR and UVA.
MYU-3L (above) and AY27 (below) cells were cultured in white walled
multi-well plates. Cells were treated with 200mM S
4TdR, 10kJm
 2 UVA or
a combination of both; four wells were set up for each treatment group.
Twenty-four hours after UVA exposure, 50ml of Caspase-Glo 3/7 reagent
was added to each well and incubated for 1h at room temperature.
Luminescence was measured in a plate reading luminometer. The graphs
above represent the mean±s.e.m. of three independent experiments each
consisting of four replicates.
Table 2 S
4TdR incorporation into DNA in different tissues following intravenous (160mgmk
 1) or intravesical (16mg in 4ml for 2h) administration.
Amount of S
4TdR incorporated into tissue DNA (% thymidine replaced by S
4TdR (mean±s.d.))
Route of S
4TdR administration
and time point of tissue extraction Control bladder Bladder tumour Kidney Liver Skin Eye
Intravenous S
4TdR
2h Undetectable 0.0018 (0.0002) 0.0016 (0.0010) 0.0050 (0.0040) 0.0008 (0.0004) 0.0003 (0.0002)
20h 0.0055 (0.0002) 0.0140 (0.0006) 0.0040 (0.0030) 0.0200 (0.0100) 0.0005 (0.0004) Undetectable
Intravesical S
4TdR
Time 0 0.0010 (0.0008) 0.0040 (0.0100) 0.0014 (0.0007) 0.0049 (0.003) 0.0008 (0.0003) 0.0002 (0.0001)
4h 0.0010 (0.0005) 0.0028 (0.0010) 0.0005 (0.0003) 0.0062 (0.005) 0.0004 (0.0001) 0.0003 (0.0002)
20h Undetectable 0.0019 (0.00003) 0.0004 (0.0003) 0.0055 (0.0020) Undetectable Undetectable
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4TdR plus UVA. All groups contained five
rats. MYU-3L tumour cells were instilled in all rat bladders using
the intravesical tumour model described above. Five days after
implantation, rats in the treatment arm and rats in the S
4TdR only
control group were given S
4TdR intravenously (160mgkg
 1)o r
intravesically (16mg in 0.4ml). After 20h, the treatment groups
and the UVA only control group were anaesthetised and UVA
(5kJm
 2) delivered into the bladders via an optical fibre. The
control groups were anaesthetised and the UVA probe inserted
with no UVA delivery. Fifteen days after the UVA treatment
(3 weeks post-tumour implantation), rats were killed. Bladders
were removed, weighed to assess tumour bulk, and formalin-fixed
for histopathological analysis and tumour staging.
All rats survived in good condition until the end of the study,
except for one animal from the UVA only group that displayed
significant weight loss and signs of stress. It was killed on day 19
and found to have bilateral pyelonephritis with renal micro-
abscesses and patchy renal infarction. Histological examination
revealed a large locally advanced stage pT3 bladder tumour.
Tumours failed to take in three rats; one each from the no-
treatment control arm, the intravesical S
4TdR only arm and the
intravenous S
4TdR only arm (Figure 6). The bladders from these
animals were similar to normal bladders in weight and appeared
histologically normal with no evidence of tumour or inflammation.
With the exception of the group that received intravenous S
4TdR
and UVA, all other animals developed advanced tumours. Each
bladder weighed 40.3g and histological examination confirmed
the presence of advanced carcinoma.
Post-treatment bladder changes were observed in three of the
five animals that received intravenous S
4TdR and UVA (Figure 6).
Macroscopic evaluation of the bladders from the three responders
revealed some enlargement compared with normal bladders, but
significantly less than that of tumour-bearing bladders. Histolo-
gical examination revealed no evidence of tumour cells. However,
there was epithelial proliferation and inflammation with lympho-
cytes, histiocytes, lymphocytes and eosinophils in addition to
haemosiderin deposition. There was no evidence of fibrosis. These
findings suggested a proliferative reparatory response with reactive
urothelial hyperplasia at the site of inflammation. Importantly,
each of the bladders from the responding animals were distinctly
different from those in which the tumour failed to implant and
from normal bladders that did not show any evidence of
inflammation. The bladders of the other two animals in this
treatment arm, which were not considered to be treatment
responses, contained locally advanced tumours that were macro-
scopically and histologically identical to the tumours observed in
the control groups.
In the group treated with intravesical S
4TdR and UVA there was
no evidence of response to the treatment. There were no
observable differences in the macroscopic appearances of the
bladders compared with the untreated tumour control groups and
microscopic evaluation revealed locally advanced tumours.
DISCUSSION
Evidence for the potential use of S
4TdR as a UVA photosensitising
agent comes from in vitro work with cultured human cells (Massey
et al, 2001; Reelfs et al, 2007). Those initial studies indicated that
S
4TdR is a nontoxic thymidine analog that is incorporated to
significant levels into DNA.
Measurements of LC/MS showed that S
4TdR is incorporated into
the DNA of bladder carcinoma cells in vitro and can replace up to
almost 1% of DNA thymidine without significantly affecting cell
growth. Even though all measurements were made after two cell
doublings, the extent of S
4TdR DNA substitution was related to the
rate of cell division of each of the cell lines. The AY27 cells had the
shortest cell-doubling time and S
4TdR incorporation in these cells
was the greatest. Conversely, RT4 cells grew more slowly and had
the lowest rate of S
4TdR incorporation. These results support the
idea that in cells with faster replication, thymidine salvage is
important to sustain DNA turnover. Therefore, tumours will
incorporate more S
4TdR than healthy urothelium, as confirmed by
the greater incorporation in bladder tumours compared with
normal bladder in the orthotopic model.
The presence of S
4TdR in DNA sensitised each of the cell lines to
subsequent UVA exposure. The growth inhibitory effect was dose
dependent for both UVA dose and S
4TdR concentration. Even very
low, nontoxic, doses of both S
4TdR (10mM) and UVA (5kJm
 2)
combined to produce a significant growth inhibition.
The TS inhibitor, raltitrexed, augmented DNA S
4TdR incorpora-
tion in all cell lines and acted as a dose modifier for UVA
sensitivity. Pretreatment with IC5 concentrations of raltitrexed
increased S
4TdR incorporation by factors of between 4 and 20. The
effect of raltitrexed was particularly marked in the cells (RT4 and
MYU-3L) in which S
4TdR incorporation was lowest. These two cell
lines had the slowest growth rates and this observation is
consistent with the dependence of S
4TdR incorporation on active
thymidine salvage mediated by TK, which is upregulated in rapidly
growing cells. A reduced reliance on TS-mediated de novo
pyrimidine nucleotide synthesis in the rapidly growing MBT2
and AY27 cells results in a less dramatic effect of raltitrexed-
mediated TS inhibition on S
4TdR incorporation. In all cases, the
increased incorporation of S
4TdR was associated with a heightened
sensitivity to UVA.
Treatment with S
4TdR/UVA induces DNA adducts that sig-
nificantly retard DNA migration in the Comet assay. This effect
was partially reversed by proteinase K digestion, indicating that
S
4TdR/UVA causes the formation of DNA–protein crosslinks.
These are likely to be difficult lesions for the DNA repair
machinery to deal with and they may be a significant contributor
to the cell death by apoptosis that was observed as a consequence
of S
4TdR/UVA treatment.
Thiothymidine had no overt toxic effects in rats following either
intravesical or intravenous administration of S
4TdR. Furthermore,
there was no significant incorporation of S
4TdR into DNA of skin
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Figure 6 Assessment of tumour burden following S
4TdR and UVA
treatment in rats. Bladders were excised and weighed following
thiothymidine and UVA treatment. Tumours failed to establish in three
rats (circled black). Responses in the intravenous S
4TdR and UVA group
are circled in grey.
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sand eye, the two tissues most susceptible to photosensitisation.
Significant incorporation was noted in liver and kidney, tissues
that are not normally exposed to UVA. Significant incorporation
into the DNA of bladder tumours was observed following
intravenous or intravesical administration of S
4TdR. The levels
of circulating thymidine are particularly high in rats (5–8mM)
compared to humans (0.05mM) and to that in standard culture
medium (0.02mM). As S
4TdR has to compete for cellular uptake
against this high background level of thymidine, this suggests that
S
4TdR/UVA may be even more effective in humans. Intravenous
administration produced a significant level of S
4TdR incorporation
into bladder tumour DNA. The DNA S
4TdR level at 2h was
somewhat higher following intravesical administration, however,
the experimental protocol required that UVA irradiation was
performed 20h after S
4TdR was administered.
No antitumour response was seen following treatment with
intravesical S
4TdR (16mg) and UVA (5kJm
 2). The time interval
between S
4TdR administration and UVA delivery is the factor most
likely to account for this failure to respond. Based on our DNA
S
4TdR measurements, the optimum time for UVA delivery would
have been immediately following S
4TdR instillation. The con-
straints of the in vivo project licence precluded this treatment
option, however.
Three out of the five rats treated with intravenous S
4TdR and
UVA had visible and histological bladder appearances which were
markedly different from control rats bladder. Microscopic
examination indicated a proliferative repair process with no
evidence of tumour cells. This was in contrast to the rats in which
tumours failed to take and in which the bladders exhibited normal
histology. These histological differences are consistent with an
inflammatory process representing repair in the treated animals,
and suggesting that their tumours regressed following S
4TdR and
UVA treatment. The timing of UVA administration following
intravenous S
4TdR appeared to be more favourable than for
intravesical administration and DNA S
4TdR was maximal at this
time. As S
4TdR incorporation into DNA in this in vivo model was
less than that seen to be optimal in in vitro experiments, some
other mechanism of antitumour effect may be operating. Further
investigations would be needed to determine other potential effects
of S
4TdR/UVA, perhaps on tumour vascularisation.
Following the in vivo treatments, an active inflammatory process
was observed with no evidence of fibrosis. However, fibrosis can be
a late complication following intravesical BCG and radiotherapy
treatment in humans, which can be functionally disabling. Fibrosis
could also be a potential adverse effect of local photodynamic
treatment. Urodynamic assessment of rats bladder compliance
following photodynamic treatment with 5-aminolavulenic acid
(5-ALA) and red light (630nm) did not previously show any
functional changes post-treatment (Xiao et al, 2003). There have
been reports of severe fibrosis requiring cystectomy in small series
of 5-ALA treatment in humans (Walther, 2000).
Thiothymidine is a potent UVA photosensitiser in vitro. The
in vivo work presented here provides the first indication that
S
4TdR is nontoxic in animals and may have potential as an
anticancer treatment. It may offer an alternative to existing
therapies for hyperproliferative diseases such as cancer, where a
photodynamic approach is possible. This study offers a proof of
principle that S
4TdR/UVA can be effective in vivo. Further work
will be aimed at confirming these promising findings and
optimising the timing, dose and route of S
4TdR administration
in an in vivo setting as a step towards designing a clinical
feasibility study.
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